Intravenous Regadenoson Versus Intravenous Adenoscan® for Fractional Flow Reserve (FFR)

Completed · Not applicable

Conditions studied: Coronary Artery Disease

In brief

The purpose of this study is to demonstrate that intravenous regadenoson is equivalent to intravenous Adenoscan® for the physiological assessment of intermediate coronary lesions.

Key facts

Study ID

NCT01482169

Run by

Ochsner Health System

People needed

48

Starts

2012-03-01

Expected to finish

2014-09-01

Last updated by the study team

2018-05-11

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients undergoing elective left heart catheterization
• Age ≥ 18 years (female not of child bearing potential)
• Able to provide written informed consent

You may not qualify if…

• Contraindications to administration of either Adenoscan® or Regadenoson
• High degree AV block, sick sinus syndrome without a functioning pacemaker
• Symptomatic bradycardia
• Recent STEMI (< 5 days)
• Recent NSTEMI (<5 days) if the peak CK is > 1000 IU
• Dipyridamole use within 24 hours
• Adenoscan® is contraindicated (hypersensitivity to Adenoscan®, Regadenoson, or aminophylline
• Known severe bronchoconstrictive lung disease

Where it is running

• Ochsner Medical Center — New Orleans, Louisiana, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.